Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Var2 Pharmaceuticals
Taproot Health
TopAlliance Biosciences
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dana-Farber Cancer Institute
Valerio Therapeutics
Valerio Therapeutics
INSYS Therapeutics Inc
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
Case Comprehensive Cancer Center